Manufacture of 261904-39-6 (2R)-3-Bromo-2-Hydroxy-2-Methylpropionic Acid Prostate Cancer Pet Imaging Agent.

Product Description: What is GW 0742GW 0742 is a selective PPARδ agonist (EC50 = 1.1 nM) that exhibits 1,000-fold selectivity over the other human PPAR subtypes. GW 0742 exhibits time-dependent neuroprotection in low KCl-induced apoptosis in cerebellar granule neuronal cultures. Despite the neuroprotective proper

Featured Products

Product Description:
 

What is GW 0742

GW 0742 is a selective PPARδ agonist (EC50 = 1.1 nM) that exhibits 1,000-fold selectivity over the other human PPAR subtypes. GW 0742 exhibits time-dependent neuroprotection in low KCl-induced apoptosis in cerebellar granule neuronal cultures. Despite the neuroprotective properties observed, prolonged (48h) incubation with GW 0742 produced significant inherent toxicity. This cell death was determined to be apoptotic as identified with the TUNEL assay.

 

Manufacture 261904-39-6 (2R) -3-Bromo-2-Hydroxy-2-Methylpropionic Acid Prostate Cancer Pet Imaging Agents.Manufacture 261904-39-6 (2R) -3-Bromo-2-Hydroxy-2-Methylpropionic Acid Prostate Cancer Pet Imaging Agents.Manufacture 261904-39-6 (2R) -3-Bromo-2-Hydroxy-2-Methylpropionic Acid Prostate Cancer Pet Imaging Agents.Manufacture 261904-39-6 (2R) -3-Bromo-2-Hydroxy-2-Methylpropionic Acid Prostate Cancer Pet Imaging Agents.
Name
GW-0742
Synonyms
[4-[[[2-[3-fluoro-4-(trifluoromethyl)phenyl]-4-methyl-5-thiazolyl]methyl]thio]-2-methyl phenoxy]-acetic acid;
GW-610742;
GW-0742X;
C.A.S NO.
317318-84-6
Density
1.462g/cm3
Molecular formula
C21H17F4NO3S2
Molecular weight
471.48800
pKa
3.17±0.10(Predicted)
Solubility
DMSO: >5 mg/mL
Melting point
134.5-135.5 °C
Flashing point
311.514ºC
Boiling point
591.476ºC at 760 mmHg

Function:

GW 0742 activates AMP-activated protein kinase and stimulates glucose uptake in skeletal muscle tissue , and GW 501516 has been demonstrated to reverse metabolic abnormalities in obese men with pre-diabetic metabolic syndrome , most likely by stimulating fatty acid oxidation .

GW0742 has been proposed as a potential treatment for obesity and related conditions , especially when used in conjunction with a synergistic compound AICAR , as the combination has been shown to significantly increase exercise endurance in human.

Application:

GW-0742 - promotion and growth of lean muscle tissue and mass. This is extremely important for the individual suffering from a muscle wasting disease. It is the muscle wasting that at times can lead to the demise of the patient even before the disease itself.

1) Increases in strength - again, excellent for those suffering from muscle wasting diseases. Increased bone density and strength - highly beneficial to the osteoporosis patient. SARMS may prove to be one of if not the most effective osteoporosis treatments available, although official data is still inconclusive.
 
2) Fat Loss - medications with strong androgen binding affinity have been shown to promote lipolysis. How significant these six SARMS are in this regard is inconclusive.
 
3) Low to No Virilization - this is highly important to women. Many compounds (anabolicandrogenic steroids) while the same benefits of anabolic steroids can apply to women as they do men, there is often the issue of virilization.
 
4) Endurance & Conditioning - All of the pre-clinical SARMS should have a level of positive effect on muscular endurance as well as overall physical conditioning. The level of effectiveness in such regards is dependent on the SARM in question and data is still inconclusive to quantify the total effects.
 
5) Nutrient Efficiency - All of the pre-clinical SARMS should have a positive impact on nutrient efficiency to one degree or another. This refers to the ability of the body to make better use of the nutrients it consumes.

Our Delivery & Packing :

Manufacture 261904-39-6 (2R) -3-Bromo-2-Hydroxy-2-Methylpropionic Acid Prostate Cancer Pet Imaging Agents.Manufacture 261904-39-6 (2R) -3-Bromo-2-Hydroxy-2-Methylpropionic Acid Prostate Cancer Pet Imaging Agents.

Our Factory :

Manufacture 261904-39-6 (2R) -3-Bromo-2-Hydroxy-2-Methylpropionic Acid Prostate Cancer Pet Imaging Agents.Manufacture 261904-39-6 (2R) -3-Bromo-2-Hydroxy-2-Methylpropionic Acid Prostate Cancer Pet Imaging Agents.

Our Advantage:
Manufacture 261904-39-6 (2R) -3-Bromo-2-Hydroxy-2-Methylpropionic Acid Prostate Cancer Pet Imaging Agents.

Our service:
1.Supply sample
2.The packing also can be according the customers` requirment
3.Any inquiries will be replied within 24 hours

4.we provide Commerical Invoice, Packing List, Bill of loading, COA , Health certificate and Origin certificate. If your markets have any special requirements, let us know.
5.Factory price.

6.Prompt delivery. We have good cooperation with many professional forwarders, We can send the products to you once you confirm the order.

Contact us

Please feel free to give your inquiry in the form below We will reply you in 24 hours